Gastrointestinal Therapeutics Market Expected to Reach $64.5 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Gastrointestinal Therapeutics Market," The gastrointestinal therapeutics market size was valued at $39.5 billion in 2022, and is estimated to reach $64.5 billion by 2032, growing at a CAGR of 5% from 2023 to 2032.

Gastrointestinal therapeutics pertains to the branch of medical science focused on the diagnosis, treatment, and management of disorders affecting the gastrointestinal tract, encompassing the esophagus, stomach, small intestine, large intestine, and rectum. This field involves the development and application of medical interventions, including pharmacological and non-pharmacological approaches, to address a wide spectrum of gastrointestinal diseases and conditions.
The increase in prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and peptic ulcers drives the demand for gastrointestinal therapeutic which propels the gastrointestinal therapeutics market trends. In addition, the increase in the geriatric population suffering from gastrointestinal disorders, surge in demand for effective treatment options, and rise in prevalence of ulcerative colitis and Crohn’s disease are the major factors that drive the market growth.  
As the global population ages, there is a higher incidence of gastrointestinal disorders associated with age, such as diverticulosis, constipation, and gastroesophageal disorders. This demographic trend drives the demand for therapies that cater to older individuals' unique needs. Thus, the rise in geriatric population contributes toward the market growth. For instance, according to the 2022 factsheet of World Health Organization (WHO), by 2030, 1 in 6 people in the world is projected to be aged 60 years or over. By 2050, the world population of people aged 60 years and older is projected to be 2.1 billion. The number of people aged 80 years or older is expected to reach 426 million by 2050.  
The gastrointestinal therapeutics market size is segmented into drug class, application, distribution channel, and region. On the basis of drug class, the market is categorized into biologics, proton pump inhibitors, aminosalicylates, antacids, laxatives, H2 antagonists, and others. The biologics segment dominated market share in 2022 owing to increase in prevalence of inflammatory bowel disease and related disorders, coupled with the efficacy of biologics in providing symptom relief and promoting healing, has driven their widespread adoption. 
On the basis of application, the gastrointestinal therapeutics industry is categorized into inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The inflammatory bowel disease segment is further categorized into Crohn’s disease and ulcerative colitis. The inflammatory bowel disease segment accounted for the largest gastrointestinal therapeutics market share in 2022 and is expected to register the highest CAGR during the forecast period. 
This is attributed to an increase in prevalence of inflammatory bowel disease, including Crohn's disease and ulcerative colitis, which has led to a higher patient population seeking medical treatment and management. In addition, rise in awareness among both patients and healthcare professionals, and the availability of a range of therapeutic options, including biologics and other gastrointestinal drugs, have contributed to the segment dominance. 
On the basis of distribution channel, the gastrointestinal therapeutics market analysis is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. The drug stores and retail pharmacies segment occupied the largest gastrointestinal therapeutics market share in 2022 owing to the widespread accessibility, established distribution networks, patient engagement capabilities, collaborative efforts with healthcare providers, and convenient medication delivery services. These factors collectively make drug stores and retail pharmacies a preferred choice for patients seeking gastrointestinal medications, thereby driving market growth in this segment. 
However, the online providers segment exhibited the fastest CAGR growth during the gastrointestinal therapeutics market forecast period. This is attributed to a wide range of gastrointestinal therapeutics from various manufacturers and suppliers, eliminating the need for physical visits to pharmacies or healthcare facilities. In addition, the rise in popularity of online pharmacies and surge in number of users preferring online pharmacies further drive the segment growth. 
Region wise, North America dominated the gastrointestinal therapeutics industry share, in terms of revenue, owing to an increase in cases of gastrointestinal diseases, presence of major key players, and rise in healthcare expenditure. In addition, a rise in regulatory product approvals is expected to drive market growth in the region during the forecast period. For instance, in April 2021, Teva Pharmaceuticals USA, Inc., announced the launch of its 1000 mg strength generic version of Casana (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis), in the U.S. 
However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for development of treatment options for gastrointestinal diseases such as inflammatory bowel disease, large patient population, rise in healthcare expenditure drive the growth of the market during the forecast period. In addition, surge in awareness leading to early detection and diagnosis of gastrointestinal conditions thereby drive the demand for gastrointestinal therapeutics as a treatment option and propels the market in this region. 

Key Findings of the Study 

• On the basis of drug class, the biologics segment was largest contributor to the market in 2022. 
• On the basis of application, the inflammatory bowel disease segment was largest contributor to the market in 2022. 
• On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period. 
• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.